Abstract
In hospitals, the transmission of antibiotic-resistant bacteria (ARB) may occur via biofilms present in sink drains, which can lead to infections. Despite the potential role of sink drains in the transmission of ARB in nosocomial infections, routine surveillance of these drains is lacking in most hospitals. As a result, there is currently no comprehensive understanding of the transmission of ARB and the dissemination of antimicrobial resistance genes (ARGs) and associated mobile genetic elements (MGEs) via sink drains. This study employed a multifaceted approach to monitor the total aerobic bacterial flora as well as the presence of carbapenemase-producing Enterobacterales (CPEs), the microbiota and the resistome of sink drain biofilms (SDBs) and hospital wastewater (WW) of two separate intensive care units (ICUs) in the same healthcare facility in France. Samples of SDB and WW were collected on a monthly basis, from January to April 2023, in the neonatal (NICU) and the adult (AICU) ICUs of Grenoble Alpes University Hospital. In the NICU, sink drain disinfection with surfactants was performed routinely. In the AICU, however, routine disinfection is not carried out. No CPEs were isolated from SDBs in either ICU by bacterial culture. Culture-independent approaches revealed an overall distinct microbiota composition of the SDBs in the two units. The AICU SDBs were dominated by potential Gram-negative bacterial pathogens including Pseudomonas, Stenotrophomonas, Staphylococcus, and Klebsiella, while the NICU SDBs were dominated by the Gram-negative genera Achromobacter, Serratia, and Acidovorax, as well as the Gram-positive genera Weisella and Lactiplantibacillus. In contrast, the resistome of the SDBs exhibited no significant differences between the two units, indicating that the abundance of ARGs and MGEs is independent of microbiota composition and disinfection practices. Investigation of the WW that connected to the respective ICUs revealed that the WW from the AICU exhibited a more diverse aerobic flora than the WW from the NICU. In addition, the AICU WW yielded 15 CPEs, whereas the NICU WW yielded a single CPE. The microbiota of the NICU and AICU WW samples differed from their respective SDBs and exhibited distinct variations over the four-month period. It is noteworthy that the WW from the AICU contained a greater number of genes conferring resistance to quinolones and integron integrase genes, whereas the NICU exhibited a higher abundance of streptogramin resistance genes. The results of our study demonstrated that the resistome of the hospital SDBs in the two ICUs of the investigated healthcare institute is independent of the microbiota, the environment, and the local disinfection measures. However, a difference was observed in the prevalence of CPEs in the WW pipes collecting the waste from the investigated drains. These findings offer valuable insights into the resilience of resistance genes in SDBs in ICUs, underscoring the necessity for innovative strategies to combat antimicrobial resistance in clinical environments.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study was funded by the TIMC laboratory and by the Association-Asposan, Montbonnot-Saint-Martin, France
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
According to the French law, submission to an IRB and patient consents are not required for retrospective studies based on existing healthcare systems data. However, in accordance with the Privacy of Individually Identifiable Health Information law, the research was declared to the Data Protection Officer of Grenoble Alpes University Hospital, France. The study protocol was reviewed by the clinical research direction of Grenoble Alpes University Hospital, France. The individual-level data had been de-identified (hence anonymized) prior to use in our study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors Sequencing data are available online at the ENA database, accession number: PRJEB83107
